Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Final Evaluation Of a Prospective, Non-Interventional Study On Efficacy and Tolerability Of a New Generation VWF/FVIII Concentrate In The Treatment Of Von Willebrand Disease

Sonja Alesci, MD, Mario Von Depka, Jennifer Feddern, Susan Halimeh, MD, Oliver Hegener, PhD, Janos Kadar, Wolfgang A. Miesbach, MD, PhD, Ulrike Nowak-Göttl, Inge Scharrer, MD, PhD

Blood (2013) 122 (21): 4775.

https://doi.org/10.1182/blood.V122.21.4775.4775

Published: 2013

Journal Articles

Pharmacokinetic Evaluation of a Newly Introduced Von Willebrand Factor Concentrate At Two London Haemophilia Centres

Oliver Hegener, PhD, Natasha M Wiles, BSc, MBBS, MRCP, MRCPath, Anne Wareing, Bella Madan, MD, MRCP, FRCPath, Steve K Austin, Dr

Blood (2012) 120 (21): 3384.

https://doi.org/10.1182/blood.V120.21.3384.3384

Published: 2012

Journal Articles

Descriptive Evaluation of Age-Related Differences in Clinical Manifestation and Treatment of Von Willebrand's Disease in an Open-Label, Prospective, Non-Interventional Study (wilate ® -SET)

Oliver Hegener, PhD, Inge Scharrer, MD, PhD, Jennifer Feddern, Wolfgang A. Miesbach V, MD, PhD, Mario Von Depka, Janos Kadar

Blood (2012) 120 (21): 4630.

https://doi.org/10.1182/blood.V120.21.4630.4630

Published: 2012

Journal Articles

A Neonate with Type 3 Von Willebrands Disease and Life Threatening Bleeding Treated Successfully with a FVIII/VWF Concentrate (wilate®)

Oliver Hegener, PhD, Jemma Efford, Jack L Bartram, Lesley Henderson, Kate Khair

Blood (2012) 120 (21): 4633.

https://doi.org/10.1182/blood.V120.21.4633.4633

Published: 2012

Journal Articles

Assessing Haemostatic Efficacy In VWF/FVIII Replacement Therapy Trials Utilizing Subjective Vs. Objective Criteria – a Way to Improve Comparability and Accuracy of Clinical Outcome.

Craig M. Kessler, MD, Bruce A. Schwartz, PhD, Oliver Hegener, Olaf Walter, MD, Sigurd Knaub, PhD

Blood (2010) 116 (21): 1424.

https://doi.org/10.1182/blood.V116.21.1424.1424

Published: 2010

NARROW

Final Evaluation Of a Prospective, Non-Interventional Study On Efficacy and Tolerability Of a New Generation VWF/FVIII Concentrate In The Treatment Of Von Willebrand Disease

Pharmacokinetic Evaluation of a Newly Introduced Von Willebrand Factor Concentrate At Two London Haemophilia Centres

Descriptive Evaluation of Age-Related Differences in Clinical Manifestation and Treatment of Von Willebrand's Disease in an Open-Label, Prospective, Non-Interventional Study (wilate ® -SET)

A Neonate with Type 3 Von Willebrands Disease and Life Threatening Bleeding Treated Successfully with a FVIII/VWF Concentrate (wilate®)

Assessing Haemostatic Efficacy In VWF/FVIII Replacement Therapy Trials Utilizing Subjective Vs. Objective Criteria – a Way to Improve Comparability and Accuracy of Clinical Outcome.

Email alerts

ASH Publications

American Society of Hematology

Final Evaluation Of a Prospective, Non-Interventional Study On Efficacy and Tolerability Of a New Generation VWF/FVIII Concentrate In The Treatment Of Von Willebrand Disease

Pharmacokinetic Evaluation of a Newly Introduced Von Willebrand Factor Concentrate At Two London Haemophilia Centres

Descriptive Evaluation of Age-Related Differences in Clinical Manifestation and Treatment of Von Willebrand's Disease in an Open-Label, Prospective, Non-Interventional Study (wilate ® -SET)

A Neonate with Type 3 Von Willebrands Disease and Life Threatening Bleeding Treated Successfully with a FVIII/VWF Concentrate (wilate®)

Assessing Haemostatic Efficacy In VWF/FVIII Replacement Therapy Trials Utilizing Subjective Vs. Objective Criteria – a Way to Improve Comparability and Accuracy of Clinical Outcome.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only